An Open Label Extension Study of HT-100 in Patients With Duchenne Muscular Dystrophy Who Have Completed Protocol HALO-DMD-01
Phase of Trial: Phase II
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Halofuginone (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Acronyms HALO
- Sponsors Akashi Therapeutics; Halo Therapeutics
- 06 Jul 2017 Status changed from suspended to discontinued as dosing stopped.
- 03 Feb 2016 Status changed from active, no longer recruiting to suspended as dosing suspended temporarily, according to ClinicalTrials.gov record.
- 25 Jan 2016 According to an Akashi Therapeutics media release, dosing and enrollment in this trial has been suspended based on discussions with the FDA.